Sanjay B. Patil
Research Subjects
Sanjay B. Patil has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Krutika K. Sawant
New Drug Delivery Systems Laboratory, Pharmacy Department, TIFAC Center of Relevance and Excellence in NDDS, The M. S. University of Baroda, Vadodara 390002, Gujarat, India
4 shared publicationsAnil Babbar
Ministry of Defence, Government of India, Institute of Nuclear Medicine and Allied Sciences, Delhi 110054, India
2 shared publicationsAnil Mishra
Ministry of Defence, Government of India, Institute of Nuclear Medicine and Allied Sciences, Delhi 110054, India
2 shared publicationsRashi Mathur
Ministry of Defence, Government of India, Institute of Nuclear Medicine and Allied Sciences, Delhi 110054, India
2 shared publications- Swapnil Jain
Department of Pharmaceutics, H.R. Patel Institute of Pharmaceutical Education and Research Shirpur
2 shared publications - Ankur Kaul
Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi 110054, India
1 shared publication
Latest Publications
- 25 July 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (9) , 104437
Formulation development and evaluation of nasal in situ gel of promethazine hydrochloride- part II: Pharmacokinetic evaluation and bioavailability studies
- 25 July 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (9) , 104437
Formulation development and evaluation of nasal in situ gel of promethazine hydrochloride- part II: Pharmacokinetic evaluation and bioavailability studies
- Open Access
- 31 October 2025
- Published by Creative Pharma Assent in Journal of Applied Pharmaceutical Research
- Vol. 13 (5) , 287-298
Formulation development and characterization of flucinolone acetonide nanoemulsion for ocular drug delivery system
Background: The purpose of this study is to enhance and demonstrate the effectiveness of the corticosteroid drug fluocinolone acetonide in the form of an ophthalmic nanoemulsion. This formulation is designed to improve targeted delivery and ocular penetration, making it suitable for the treatment of conditions such as age-related macular degeneration, diabetic macular edema, and posterior uveitis. Methodology: To formulate the nanoemulsion, we used polysorbate 20 and a castor oil derivative known as HCO-40. The continuous emulsification method was employed to prepare the formulation. Initial batches were tested for key properties, including pH, osmolality, drug content, globule size, and zeta potential. A factorial design approach was applied, in which polysorbate 20 and the castor oil derivative (Cremophor RH 40) were considered independent variables. The nanoemulsion was further evaluated for ocular irritancy using cell line analysis, in vitro scleral permeability, and the Hen’s Egg Chorioallantoic Membrane (HET-CAM) test. Results and Discussion: The optimized batch of the nanoemulsion showed a penetration rate exceeding 80% and a small globule size of 19–20 nm. In vitro tests using human retinal pigment epithelial (ARPE-19) cells and the HET-CAM test indicated that the formulated nanoemulsion is non-toxic and non-irritating to the eye, confirming its cytocompatibility. Conclusion: The developed optimized nanoemulsion formulation of flucinolone acetonide provides improved targeting, non-invasive administration & enhanced patient compliance when used as a topical eye drop for treating ocular diseases such as age-related macular degeneration and posterior uveitis.
- 31 October 2025
- Published by Creative Pharma Assent in Journal of Applied Pharmaceutical Research
- Vol. 13 (5) , 287-298
Open AccessFormulation development and characterization of flucinolone acetonide nanoemulsion for ocular drug delivery system
Background: The purpose of this study is to enhance and demonstrate the effectiveness of the corticosteroid drug fluocinolone acetonide in the form of an ophthalmic nanoemulsion. This formulation is designed to improve targeted delivery and ocular penetration, making it suitable for the treatment of conditions such as age-related macular degeneration, diabetic macular edema, and posterior uveitis. Methodology: To formulate the nanoemulsion, we used polysorbate 20 and a castor oil derivative known as HCO-40. The continuous emulsification method was employed to prepare the formulation. Initial batches were tested for key properties, including pH, osmolality, drug content, globule size, and zeta potential. A factorial design approach was applied, in which polysorbate 20 and the castor oil derivative (Cremophor RH 40) were considered independent variables. The nanoemulsion was further evaluated for ocular irritancy using cell line analysis, in vitro scleral permeability, and the Hen’s Egg Chorioallantoic Membrane (HET-CAM) test. Results and Discussion: The optimized batch of the nanoemulsion showed a penetration rate exceeding 80% and a small globule size of 19–20 nm. In vitro tests using human retinal pigment epithelial (ARPE-19) cells and the HET-CAM test indicated that the formulated nanoemulsion is non-toxic and non-irritating to the eye, confirming its cytocompatibility. Conclusion: The developed optimized nanoemulsion formulation of flucinolone acetonide provides improved targeting, non-invasive administration & enhanced patient compliance when used as a topical eye drop for treating ocular diseases such as age-related macular degeneration and posterior uveitis.
- Open Access
- 1 July 2025
- Published by Horizon Research Publishing Co., Ltd. in Advances in Pharmacology and Pharmacy
- Vol. 13 (3) , 287-296
Advancements in Fast Dissolving Oral Films
The term "fast dissolving oral drug delivery system" refers to a system that dissolves or disintegrates in a matter of seconds or minutes when held in the mouth without water and swallowed. Oral fast dissolving films have emerged as a viable drug delivery technique in recent years, owing to a number of advantages for pediatrics and geriatric patients who have difficulty in swallowing. These little, thin oral film strips are meant to make medicine administration easier when the film is placed on or under the tongue. These films allow the medicine to be delivered directly into the bloodstream via buccal or sublingual routes. Oral films have been shown to improve the onset of action, reduce dosage, and increase bioavailability. This review article discusses the history, benefits, and limitations of oral rapid dissolving films, as well as formulation considerations, manufacturing processes, evaluation parameters, packaging, and marketed products. Due to its unique properties, novel attributes, competitive standing, and cost adequacy, it can be inferred that it is one of the fastest-growing dosage forms with a lot of potential, particularly for commercial applications.
- 1 July 2025
- Published by Horizon Research Publishing Co., Ltd. in Advances in Pharmacology and Pharmacy
- Vol. 13 (3) , 287-296
Open AccessAdvancements in Fast Dissolving Oral Films
The term "fast dissolving oral drug delivery system" refers to a system that dissolves or disintegrates in a matter of seconds or minutes when held in the mouth without water and swallowed. Oral fast dissolving films have emerged as a viable drug delivery technique in recent years, owing to a number of advantages for pediatrics and geriatric patients who have difficulty in swallowing. These little, thin oral film strips are meant to make medicine administration easier when the film is placed on or under the tongue. These films allow the medicine to be delivered directly into the bloodstream via buccal or sublingual routes. Oral films have been shown to improve the onset of action, reduce dosage, and increase bioavailability. This review article discusses the history, benefits, and limitations of oral rapid dissolving films, as well as formulation considerations, manufacturing processes, evaluation parameters, packaging, and marketed products. Due to its unique properties, novel attributes, competitive standing, and cost adequacy, it can be inferred that it is one of the fastest-growing dosage forms with a lot of potential, particularly for commercial applications.
- 29 May 2024
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 3 (1) , 259-276
Overview of Medical Device Regulations in Singapore and Thailand
- 29 May 2024
- Published by Springer Nature in Biomedical Materials & Devices
- Vol. 3 (1) , 259-276
Overview of Medical Device Regulations in Singapore and Thailand
- Open Access
- 14 June 2023
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 71 (6) , 2355-2366
Nanocarriers for ocular drug delivery: Recent advances and future opportunities
Topical route of administration is very important and the most commonly used method of drug delivery for treatment of ocular diseases. However, due to unique anatomical and physiological barriers of eye, it is difficult to achieve the therapeutic concentration in the targeted tissue within the eye. To overcome the effect of these barriers in absorption and to provide targeted and sustained drug delivery, various advances have been made in developing safe and efficient drug delivery systems. Various formulation strategies for ocular drug delivery are used, like basic formulation techniques for improving availability of drugs, viscosity enhancers, and use of mucoadhesives for drug retention and penetration enhancers to promote drug transport to the eye. In this review, we present a summary of the current literature to understand the anatomical and physiological limitations in achieving adequate ocular bioavailability and targeted drug delivery of topically applied drugs and use of new techniques in formulating dosage forms in overcoming these limitations. The recent and future advances in nanocarrier-mediated drug delivery may have the potential to provide patient-friendly and noninvasive techniques for the treatment of diseases related to the anterior and posterior segments of the eye.
- 14 June 2023
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 71 (6) , 2355-2366
Open AccessNanocarriers for ocular drug delivery: Recent advances and future opportunities
Topical route of administration is very important and the most commonly used method of drug delivery for treatment of ocular diseases. However, due to unique anatomical and physiological barriers of eye, it is difficult to achieve the therapeutic concentration in the targeted tissue within the eye. To overcome the effect of these barriers in absorption and to provide targeted and sustained drug delivery, various advances have been made in developing safe and efficient drug delivery systems. Various formulation strategies for ocular drug delivery are used, like basic formulation techniques for improving availability of drugs, viscosity enhancers, and use of mucoadhesives for drug retention and penetration enhancers to promote drug transport to the eye. In this review, we present a summary of the current literature to understand the anatomical and physiological limitations in achieving adequate ocular bioavailability and targeted drug delivery of topically applied drugs and use of new techniques in formulating dosage forms in overcoming these limitations. The recent and future advances in nanocarrier-mediated drug delivery may have the potential to provide patient-friendly and noninvasive techniques for the treatment of diseases related to the anterior and posterior segments of the eye.
- 21 December 2022
- Published by Springer Nature in Inflammopharmacology
- Vol. 31 (1) , 253-264
Perspectives of colon-specific drug delivery in the management of morning symptoms of rheumatoid arthritis
Rheumatoid arthritis is a chronic condition that is characterized by joint pain and inflammation. It is an autoimmune disorder in which the body tissues are erroneously attacked by the immune system of the host itself. It has been evident that rheumatoid arthritis symptoms follow a 24 h circadian rhythm and exhibit high thresholds of pain, functional disability, and stiffness predominantly early in the morning. Colon-specific drug delivery systems can be utilized in the formulations to be used in the treatment of rheumatoid arthritis. The colon-specific drug delivery system has shown promising results in the treatment of different diseases at the colonic site like Crohn’s disease, ulcerative colitis, colon cancer, etc. The colon-specific drug delivery is capable of delivering the formulation at the predetermined location and predetermined time. The early morning symptoms of rheumatoid arthritis like pain and inflammation can be treated using the various approaches of the colon-specific drug delivery system because it will lead to patient compliance as the patient will not require administering the formulation immediately after waking up in the morning. This review also explains the immunological factors which may trigger rheumatoid arthritis in human beings. It further explores conventional approaches like pH-dependant, microorganisms-driven, pressure-controlled, and time-dependant formulations. By employing two or more conventional approaches given above the various novel approaches have been designed to eliminate the drawbacks of individual techniques.
- 21 December 2022
- Published by Springer Nature in Inflammopharmacology
- Vol. 31 (1) , 253-264
Perspectives of colon-specific drug delivery in the management of morning symptoms of rheumatoid arthritis
Rheumatoid arthritis is a chronic condition that is characterized by joint pain and inflammation. It is an autoimmune disorder in which the body tissues are erroneously attacked by the immune system of the host itself. It has been evident that rheumatoid arthritis symptoms follow a 24 h circadian rhythm and exhibit high thresholds of pain, functional disability, and stiffness predominantly early in the morning. Colon-specific drug delivery systems can be utilized in the formulations to be used in the treatment of rheumatoid arthritis. The colon-specific drug delivery system has shown promising results in the treatment of different diseases at the colonic site like Crohn’s disease, ulcerative colitis, colon cancer, etc. The colon-specific drug delivery is capable of delivering the formulation at the predetermined location and predetermined time. The early morning symptoms of rheumatoid arthritis like pain and inflammation can be treated using the various approaches of the colon-specific drug delivery system because it will lead to patient compliance as the patient will not require administering the formulation immediately after waking up in the morning. This review also explains the immunological factors which may trigger rheumatoid arthritis in human beings. It further explores conventional approaches like pH-dependant, microorganisms-driven, pressure-controlled, and time-dependant formulations. By employing two or more conventional approaches given above the various novel approaches have been designed to eliminate the drawbacks of individual techniques.
- 1 March 2020
- Published by Elsevier in Journal of Crystal Growth
- Vol. 534
Pharmaceutical cocrystals of nebivolol hydrochloride with enhanced solubility
- 1 March 2020
- Published by Elsevier in Journal of Crystal Growth
- Vol. 534
Pharmaceutical cocrystals of nebivolol hydrochloride with enhanced solubility